Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

Stopped early · Phase 2

Conditions studied: Antibody-mediated Rejection, Humoral Rejection

In brief

This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients. All patients will be evaluated from the time of AMR diagnosis for 12 months.

Key facts

Study ID

NCT01895127

Run by

Brigham and Women's Hospital

People needed

11

Starts

2013-11-01

Expected to finish

2016-04-01

Last updated by the study team

2017-09-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult renal transplant recipients, men and women between 18 and 75 years of age.
• Any patient with acute graft dysfunction (elevation of creatinine above post transplant nadir)
• AND, two out of three, of the following Inclusion Criteria:
• Presence of circulating anti human leukocyte antigen (HLA) antibody (DSA "donor specific antibody").
• Histological findings compatible with Banff Class II or III AMR on transplant biopsy.
• Peritubular capillary c4d positivity on transplant biopsy.

You may not qualify if…

• Patients that have received eculizumab prior to enrolling in the study.
• Patients with ongoing non-acute antibody mediated rejection.
• Patients with predominantly chronic antibody mediated rejection or interstitial fibrosis/tubular atrophy.
• History of severe cardiac disease (e.g., New York Heart Association [NYHA] Functional Class III or IV, myocardial infarction ≤ 6 months of randomization, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases)
• Prior splenectomy
• Has a known bleeding disorder
• Has any active bacterial or other infection which is clinically significant in the opinion of the Investigator and is a contraindication to transplantation
• Has participated in any other investigational drug study or was exposed to an investigational drug or device within 30 days of screening
• Has received rituximab (Rituxan®) ≤ 3 months prior to screening
• Has received bortezomib (Velcade®) ≤ 3 months prior to screening
• Has received alemtuzumab (Campath®) ≤ 6 months prior to screening
• Need for concurrent treatment with anti thymocyte globulin (Thymoglobulin®)
• Hypersensitivity to murine proteins or to one of the product excipients
• History of illicit drug use or alcohol abuse within the previous year
• Unresolved meningococcal disease
• Pregnancy or lactation
• Current cancer or a history of cancer within the 5 years prior to screening with the exception of patients who have successfully treated non-metastatic basal or squamous cell carcinoma of the skin; carcinoma in situ of the cervix; or breast carcinoma in situ
• Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient Active infection with Hepatitis B (HBV), Hepatitis C (HCV) or human immunodeficiency virus (HIV)

Where it is running

• UCSF Medical Center — San Francisco, California, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• University of Michigan Medical Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.